Ikarian Capital’s Harmony Biosciences HRMY Stock Holding History

Ikarian Capital’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-86,035	Closed	-$4.2M	–	131
2022 Q2	$4.2M	Buy	+86,035	New	+$3.87M	0.77%	42

Other funds holding HRMY

Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Ikarian Capital's HRMY Position: Q3 2022 in Review

Ikarian Capital sold out of Harmony Biosciences (HRMY) in Q3 2022, closing a stake of 86,035 shares — an estimated $4.2M sold.

Ikarian Capital first reported a position in HRMY in Q2 2022 and held it in 1 quarter. The position peaked at $4.2M in Q2 2022. 203 funds tracked by Wall St. Rank hold HRMY as of Q3 2022.

Ikarian Capital reported no remaining Harmony Biosciences position as of Q3 2022 after selling out during the quarter.
Ikarian Capital sold 86,035 Harmony Biosciences shares in Q3 2022, an estimated $4.2M.
Ikarian Capital first reported a position in Harmony Biosciences in Q2 2022 and held it in 1 quarter.
Ikarian Capital's Harmony Biosciences position peaked at $4.2M in Q2 2022.
203 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2022.

Based on Ikarian Capital's 13F filing for Q3 2022, filed 14 Nov 2022.